817 related articles for article (PubMed ID: 33183286)
21. The application of exosomes as a nanoscale cancer vaccine.
Tan A; De La Peña H; Seifalian AM
Int J Nanomedicine; 2010 Nov; 5():889-900. PubMed ID: 21116329
[TBL] [Abstract][Full Text] [Related]
22. Exosomes-based cell-free cancer therapy: a novel strategy for targeted therapy.
Dutta A
Immunol Med; 2021 Jun; 44(2):116-123. PubMed ID: 32924880
[TBL] [Abstract][Full Text] [Related]
23. Exosome-like Nanovectors for Drug Delivery in Cancer.
Arrighetti N; Corbo C; Evangelopoulos M; Pastò A; Zuco V; Tasciotti E
Curr Med Chem; 2019; 26(33):6132-6148. PubMed ID: 30182846
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer.
Pitt JM; Charrier M; Viaud S; André F; Besse B; Chaput N; Zitvogel L
J Immunol; 2014 Aug; 193(3):1006-11. PubMed ID: 25049431
[TBL] [Abstract][Full Text] [Related]
25. Role of exosomes in immune regulation.
Li XB; Zhang ZR; Schluesener HJ; Xu SQ
J Cell Mol Med; 2006; 10(2):364-75. PubMed ID: 16796805
[TBL] [Abstract][Full Text] [Related]
26. Personalized medicine and back-allogeneic exosomes for cancer immunotherapy.
Samuel M; Gabrielsson S
J Intern Med; 2021 Feb; 289(2):138-146. PubMed ID: 31359504
[TBL] [Abstract][Full Text] [Related]
27. A Comprehensive Review on Exosome: Recent Progress and Outlook.
Agarwal P; Anees A; Harsiddharay RK; Kumar P; Tripathi PK
Pharm Nanotechnol; 2023 May; ():. PubMed ID: 37231760
[TBL] [Abstract][Full Text] [Related]
28. Exosome: a significant nano-scale drug delivery carrier.
Peng H; Ji W; Zhao R; Yang J; Lu Z; Li Y; Zhang X
J Mater Chem B; 2020 Sep; 8(34):7591-7608. PubMed ID: 32697267
[TBL] [Abstract][Full Text] [Related]
29. The involvement and application potential of exosomes in breast cancer immunotherapy.
Wang Y; Ma Q; Wang T; Xing J; Li Q; Wang D; Wang G
Front Immunol; 2024; 15():1384946. PubMed ID: 38835784
[TBL] [Abstract][Full Text] [Related]
30. Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment.
Rasihashemi SZ; Sahrai H; Rezazadeh-Gavgani E; Yazdani Y; Khalaji A; Lotfinejad P
Med Oncol; 2022 Sep; 39(12):183. PubMed ID: 36071295
[TBL] [Abstract][Full Text] [Related]
31. Functions of Cancer-Derived Extracellular Vesicles in Immunosuppression.
Czernek L; Düchler M
Arch Immunol Ther Exp (Warsz); 2017 Aug; 65(4):311-323. PubMed ID: 28101591
[TBL] [Abstract][Full Text] [Related]
32. Exosomes: Powerful weapon for cancer nano-immunoengineering.
Pi YN; Xia BR; Jin MZ; Jin WL; Lou G
Biochem Pharmacol; 2021 Apr; 186():114487. PubMed ID: 33647264
[TBL] [Abstract][Full Text] [Related]
33. Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review.
Fang Z; Ding Y; Xue Z; Li P; Li J; Li F
Discov Oncol; 2022 Aug; 13(1):74. PubMed ID: 35962862
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?
Viaud S; Théry C; Ploix S; Tursz T; Lapierre V; Lantz O; Zitvogel L; Chaput N
Cancer Res; 2010 Feb; 70(4):1281-5. PubMed ID: 20145139
[TBL] [Abstract][Full Text] [Related]
35. Exosome-related Methods and Potential Use as Vaccines.
Kanlikilicer P
Methods Mol Biol; 2022; 2435():35-41. PubMed ID: 34993938
[TBL] [Abstract][Full Text] [Related]
36. Gold nanoparticle mediated cancer immunotherapy.
Almeida JP; Figueroa ER; Drezek RA
Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
[TBL] [Abstract][Full Text] [Related]
37. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases.
Tran TH; Mattheolabakis G; Aldawsari H; Amiji M
Clin Immunol; 2015 Sep; 160(1):46-58. PubMed ID: 25842185
[TBL] [Abstract][Full Text] [Related]
38. Prospects for exosomes in immunotherapy of cancer.
Mignot G; Roux S; Thery C; Ségura E; Zitvogel L
J Cell Mol Med; 2006; 10(2):376-88. PubMed ID: 16796806
[TBL] [Abstract][Full Text] [Related]
39. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
40. Exosomes in the tumor microenvironment as mediators of cancer therapy resistance.
Li I; Nabet BY
Mol Cancer; 2019 Mar; 18(1):32. PubMed ID: 30823926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
